anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Thirteen years into conflict, Syria remains one of the world's major humanitarian crises. Food insecurity has reached unprecedented levels in the country, with millions of civilians facing starvation and hunger. The key drivers of this are conflict-related, nature-induced, and, importantly, man-made policies. Semi-comprehensive sanctions against the country and donor conditionality vis-à-vis humanitarian operators' work are prime examples of the latter. These policies are inextricably linked with food insecurity in Syria and have direct and indirect impacts on it. Understanding the ongoing crisis as a complex emergency, this paper examines the interplay between sanctions, donor conditionality, and food insecurity, an understudied subject in the Syrian context. It explores how sanctions and donor conditionality influence three key dimensions of food security, namely, availability, affordability and economic access, and utilisation, and subsequently worsen the conditions confronting the Syrian population. The paper contributes to discussions on food security in conflict settings and how sanctions negatively affect civilians in targeted countries.
<P>PROBLEM TO BE SOLVED: To apply a pour point temperature-rising treatment to polyethylene glycol having a low pour point temperature at the ordinary state to provide polyethylene glycol.  <P>SOLUTION: This polyethylene glycol composition which exhibits three states of solid, solid-liquid coexisting state and liquid, when temperature is changed, and exhibits ordinarily in the solid-liquid coexisting state is characterized in that the composition comprises a mixture of two kinds of polyethylene glycols having different weight-average mol. wts. in the mol. wt. distribution. The composition is quenched from a temperature of a liquid state to a temperature of a solid state at a cooling rate of ≥2°C/min to obtain the polyethylene glycol composition whose pour point temperature is higher than a boundary temperature between the liquid state and a solid-liquid coexisting state.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The specification describes combinations of at least three amphipatic substances forming aggregate suspensions in a polar liquid. Judicious choice of system components, which differ at least 2-times to 10-times in solubility, ensures said aggregates to have extended, unusually adaptable surfaces. This is probably due to simultaneous action on said aggregates of at least two more soluble substances amongst said three system components, at least one of which is an active ingredient and preferably a drug; the third component, alternatively, can take the role of a drug. The specification further deals with the use of said combinations in pharmaceutical preparations capable of transporting drugs into the body of warm blood creatures. This is made possible by the drug loading capability of said aggregates with the highly flexible and deformable coating, which renders the resulting drug carriers highly adaptable. The specification finally reveals suitable methods and favourable conditions for carrier manufacturing and application. The specification also describes novel formulations of nonsteroidal anti-inflammatory drugs (NSAIDs) based on complex aggregates with at least three amphipatic components suspended in a suitable, e.g. pharmaceutically acceptable, polar liquid medium. Particularly disclosed is a preparation based on a combination of at least one first (membrane forming component MFC), at least one second (membrane destabilising component MDC), and at least one third (membrane destabilising component MDC) amphipatic component suspended in a suitable liquid medium in the form of corresponding mixed amphipat aggregates with extended surface(ESAs) with one or a few mixed amphipat coating(s), wherein said ESAs formed by a combination of all three said components have surfaces in contact with said liquid medium that are at least 50% more extended, on the average, than the typical surfaces of aggregates comprising the said at least one second and at least one third amphipatic component alone, at the same concentrations and, in case, after adjustment for the physico-chemical effects of resulting from the absence of said first amphipatic compound (MFC) for application, administration or transport of an active ingredient, which can be one of the three amphipatic components, especially for biological, medical, immunological, or cosmetic purposes, into and through the pores in semi-permeable barriers or other constrictions, such as through the skin of warm blood creatures or the like.
KINERET (anakinra) is a recombinant, nonglycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra). KINERET differs from native human IL-1Ra in that it has the addition of a single methionine residue at its amino terminus. KINERET consists of 153 amino acids and has a molecular weight of 17.3 kilodaltons. It is produced by recombinant DNA technology using an E colibacterial expression system. 

KINERET is supplied in single use prefilled glass syringes with 29 gauge needles as a sterile, clear, colorless-to-white, preservative free solution for daily subcutaneous (SC) administration. The solution may contain trace amounts of small, translucent-to-white amorphous proteinaceous particles. Each prefilled glass syringe contains: 0.67 mL (100 mg) of anakinra in a solution (pH 6.5) containing anhydrous citric acid (1.29 mg), disodium EDTA (0.12 mg), polysorbate 80 (0.70 mg), and sodium chloride (5.48 mg) in Water for Injection, USP.

The prefilled syringe contains an outer rigid plastic needle shield attached to an inner needle cover. The syringe or needle shield components are not made with natural rubber latex.
Patients treated with DWP14012, Naproxen will be enrolled. DDI will be evaluated.
The development of nonalcoholic fatty liver disease (NAFLD) progresses from a state of elevated intrahepatic triglycerides (IHTG) to liver inflammation, and ultimately, hepatic apoptosis and fibrosis. NAFLD is the most prevalent liver disease in the U.S., and there is a serious need to understand its progression to the advanced state, nonalcoholic steatohepatitis (NASH). Elevated de novo lipogenesis (DNL) is the unique, early event distinguishing patients with NAFLD from equally-obese participants with low IHTG. DNL is the process of liver synthesis of fatty acids (FAs) from carbohydrate. In humans, studies have shown that DNL significantly predicts the magnitude of IHTG, however, it is unknown whether the pathway plays a role in disease progression. Evidence supporting this concept includes the fact that the primary product of DNL is the saturated FA, palmitate, which in cell culture has been shown to significantly contribute to oxidative stress and inflammation. Recent rodent data show that upregulation of DNL through dietary supplementation of sucrose exacerbated the hepatotoxic effects of excess dietary FAs. A preliminary abstract presented by others at the 2017 Liver Meeting suggested that DNL may not be different between patients with low and high liver fibrosis, although these data were collected using an indirect measure of liver disease. Here, in the present study, the hypothesis will be tested directly by measuring DNL in human liver tissue and comparing it to liver histological scores (NAFLD Activity Score, NAS) from patient samples.
Group A, The patient was in the supine position then; the TAP block was given by a high frequency linear ultrasound transducer (Siemens acuson x300 3-5MHz ultrasound). After skin preparation and isolation, the transducer was placed 2 cm sub-xiphoid, then moved along the subcostal edge to identify the rectus abdominis muscle and the transversus abdominis then, a blunted tip, 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) was introduced in-plane 2-3 cm lateral to the transducer, under direct ultrasound visualization. After confirming the correct placement of the needle and the negative aspiration probe, the rest of the anaesthetic substance was injected along the subcostal line in the transversus abdominis plane 20 ml 0.25% bupivacaine on each side after aspiration to avoid intravascular placement, and the dissection of the plane was observed. The block was performed bilaterally.
BACKGROUND: Antepartum hemorrhage is defined as any bleeding from or into the genital tract during pregnancy, after the period of viability until delivery of the fetus. APH complicates 2-5% of pregnancies and is a primary cause of perinatal and maternal mortality globally. Aim of this study is to evaluate maternal and perinatal outcome in patients with APH at a tertiary care hospital.
METHODS: The present study was a cross sectional study conducted in Obstetrics and Gynaecology department of Paropakar Maternity and Women's Hospital, during a period of 5 months from December 2022 to April 2023. 50 cases of APH were enrolled with gestational age ≥ 34 weeks of gestation.
RESULTS: Incidence of APH after 34 weeks of gestation was 0.51%. The most common type of APH was abruption placenta (44%) followed by placenta previa (32%) and undetermined (24%). The age range of 26 to 30 years old accounted for the highest number of APH patients i.e., 21(42%). In placenta previa, 75% and in abruption placenta 63.64% were multigravida. APH was presented mostly between 37-40 weeks. Around 26% of the patients had anemia at the time of admission. Most common mode of delivery was cesarean section (82%). Most common maternal complications were PPH (40%), blood transfusion (28%), DIC (4%), cesarean hysterectomy (4%). Low birth weight and preterm were the most common causes of fetal complications. Maternal mortality was 2% and perinatal mortality was 18% overall.
CONCLUSIONS: APH is primary cause of maternal and perinatal morbidity and mortality. In our study, an abruption placenta was the most frequent cause of APH. Cesarean section was the most commonly used mode of delivery. PPH with blood transfusion was the most prevalent maternal complication, while fetal complications included low birth weight and preterm..
PROBLEM TO BE SOLVED: To obtain a bitter-taste suppressing agent having excellent bitter-taste suppressing effect by using a fatty acid as an active component. SOLUTION: This bitter-taste suppressing agent contains an 8-24C saturated or unsaturated fatty acid and/or fatty acid metal salt as an active component. The fatty acid may be used as it is or in a state separated and purifiedby fractionation, distillation, etc. The fatty acid can be produced from an easily available raw material by conventional method such as the hydrogenation and saponification of an oil and fat derived from animal, or vegetable raw materials with an enzyme or by chemical synthesis. Bitter taste of pharmaceuticals, foods or cosmetics is effectively suppressed by compounding 0.1-10wt.%, preferalby 0.5-3wt.% of the bitter-taste suppressing agent based on the total weight of the pharmaceuticals, etc. Especially, the bitter taste of a food can be suppressed without changing the good palatability of the food.
PURPOSE: To obtain the subject safe therapeutic agent, containing an extract of a plant belonging to the family Amaranthaceae as an active ingredient, daily usable, good in feeling of use and derived from a natural product without any side effects. CONSTITUTION: This therapeutic agent for atopic dermatitis contains an extract obtained from a seed of a plant belonging to the family Amaranthaceae [e.g. Celosia argentea L. (Celosiae Semen), Celosia cristata L., Amaranthus retroflexus L., Amaranthus caudatus L., Amaranthus patulus Bert., Amaranthus paniculatus L., Amaranthus spinosus L., Amaranthus lividus L. or Amaranthus mangostanus L.] or a powder prepared by drying the extract as an active ingredient. The therapeutic agent is blended in an amount of 1.0-100wt.% (preferably 5.0-70.0wt.%) in, e.g. a bathing agent and 0.02-100.0wt.% (preferably 2.0-100.0wt.%) in a skin-care preparation for external use. Furthermore, the extract of the plant belonging to the family Amaranthaceae is obtained by extracting a seed of the plant belonging to the family Amaranthaceae with a solvent such as a polyhydric alcohol under heated conditions or at normal temperatures.
FIELD: medicine, oncology. SUBSTANCE: invention shows the possibility of the complete inhibition of interaction of carcinogens with proteins and decrease the group of the enhanced oncological risk among industrial workers by 5-fold. Also, possibility of correction of immunoreactivity disorders associated with carcinogenesis using biologically active compounds (sage and clove essential oils) has been detected. Method can be used for preclinical prophylaxis of malignant neoplasm as oncological risk. EFFECT: improved method of prophylaxis. 4 tbl
OBJECTIVE: There is no clear evidence on the risk of gestational weight loss (GWL) for individuals with obesity. Our study aimed to assess the association between GWL and adverse perinatal outcomes among individuals with obesity.
METHODS: This population-based retrospective cohort study examined individuals with prepregnancy BMI ≥ 30 kg/m2 who had a singleton pregnancy, using Ontario, Canada, birth registry data from 2012 to 2020. The primary outcome was a composite of adverse outcomes, including perinatal death and neonatal morbidity. The association between GWL and risk of adverse perinatal outcomes was estimated using generalized estimating equation models and restricted cubic spline regression analysis. Stratified analysis was conducted by obesity class.
RESULTS: Of the 157,205 individuals with obesity, 6.1% experienced GWL. Compared with adequate gestational weight gain, GWL was associated with an increased risk of a composite of adverse perinatal outcomes (adjusted risk ratio: 1.31; 95% CI: 1.22-1.39). Similar results were observed in the stratified analysis. Restricted cubic spline regression analysis revealed that average weekly gestational weight changes displayed a nonlinear U-shaped association, with a higher risk of a composite of adverse perinatal outcomes noted in the extremities, particularly toward GWL and excessive weight gain.
CONCLUSIONS: Our findings suggest that GWL may increase the risk of adverse perinatal outcomes across all obesity classes.
Re-folded human serum albumin (rfHSA) and use thereof for anti-tumor are disclosed. The rfHSA comprises the primary amino acid sequence of naive human serum albumin, in which the rfHSA in a solution is oval shape, not fibrillar, and the naive HSA is globular. The rfHSA is used for treating cancer or a tumor in a subject in need thereof. The rfHSA may also be used as a reagent for detecting the presence of a cancer cell associated with integrin [beta]1 or serine/threonine protein kinase Akt and extracellular signal-regulated kinase 1/2 (ERK1/2) in a tumor sample or as a reagent for inhibiting phosphorylation of Akt and ERK1/2 in a cancer cell sample. A cell lysate of a cancer cell treated with rfHSA, a vaccine composition comprising the cancer cell lysate, and use thereof are also disclosed. Also disclosed is a method for preparing rfHSA.
Healthy individuals have been divided into control and study groups. Individuals in both group have same characteristics such as age, gender, and body mass index (Control Group: 35 individuals - Study Group: 35 individuals). Both group were asked to maintain their normal diets. In addition, the study group consume 20 g of dried goji berry per day and did not consume any fruit with a similar antioxidant content during the 8 weeks study period. The control group was asked to exclude goji berry and similar fruits with high antioxidant content from their diet during the 8 weeks study period. The 20 g goji berry for per day was given weekly to each individual in a study group in transparent bags. At the beginning of the study and every 15 days, food consumption record for 3 consecutive days (2 weekdays and 1 weekend), a 3-day physical activity record, and anthropometric measurements (weight, height, waist and hip circumferences, body composition analysis) were taken. Blood parameters (total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), very low density lipoprotein (VLDL), triglyceride, glucose, insulin, homeostatic model assessment of insulin resistance (HOMA-IR), HbA1c) of individuals were taken at the beginning and the end of the study.
Chronic rhinosinusitis with nasal polyps (CRSwNP) significantly impacts quality of life and often presents therapeutic challenges, with biologics like dupilumab showing promise in managing severe, uncontrolled cases. The aim of this study was to assess the influence of overweight on the effectiveness of dupilumab in patients with uncontrolled CRSwNP. This retrospective study analyzed treatment outcomes of 75 CRSwNP patients receiving dupilumab, categorizing them into underweight/normal-weight (BMI ≤ 24.9 kg/m2) and overweight/obese (BMI ≥ 25 kg/m2) groups. Outcome measures included changes in nasal polyp score (NPS) and sinonasal outcome test (SNOT-22) scores. Results demonstrated that the underweight/normal-weight group experienced significantly greater improvements in NPS and a higher rate of total NPS improvement compared to the overweight/obese group. While SNOT-22 scores improved in both groups, no significant differences were observed. Among patients with comorbid asthma, the underweight/normal-weight subgroup also showed significantly better outcomes, including greater reductions in both NPS and SNOT-22 scores. Multiple regression analysis identified BMI as an independent prognostic factor for NPS outcomes. The findings suggest that overweight/obesity adversely affects the response to dupilumab in CRSwNP, emphasizing the need for personalized treatment strategies considering BMI.
The present invention relates to a preparation technology and a production method for an integrated new formulation of a expelling stasis below the diaphragm decoction, wherein the raw materials of active ingredients comprise: 10 parts by weight of Chinese angelica, 6 parts by weight of ligusticum wallichii, 9 parts by weight of peach seeds, 6 parts by weight of red pheony root, 9 parts by weight of flying squirrel feces and the like. The production process of the integrated new formulation of expelling stasis below the diaphragm decoction comprises the following steps of: supersonic air-jet crushing, alcohol-water extraction, ultrasonic crushing extraction, water decocting concentration, supersonic spray drying, nanometer grinding, high pressure homogenization, nano particle preparation and the like. According to the invention, the advantages, such as multi-synergism, multi-target, embodied by a nano-carrier coupling technique, are focused to be taken of. After the integrated new formulation of expelling stasis below the diaphragm decoction is subjected to scale production, the production cost can be greatly reduced, the quality of products is greatly improved and the targeting property and the sustained and controlled release performance of the medicament are enhanced. The internal and external administration of the integrated new formulation of expelling stasis below the diaphragm decoction can be realized simultaneously, and can be respectively taken in four time slices according to midnight-noon ebb-flow and qi and blood flowing rule of a human body. The integrated new formulation of gexia stasis-expelling decoction can be further prepared into films and transdermal agents which are respectively stuck to different parts of a human body according to the midnight-noon ebb-flow and qi and blood flowing rule of the human body and can be directly absorbed through skin.
Gynecologic cancers can lead to gynecologic tract destruction with extension into both the gastrointestinal and urinary tracts. Recurrent disease can also affect the surrounding bony pelvis and pelvic musculature. As opposed to advanced ovarian cancer, where cytoreduction is the goal, in these scenarios, an oncologic approach to achieve negative margins is critical for benefit. Surgeries aimed at achieving a R0 resection in gynecologic oncology can have a significant impact on pelvic anatomy, and require reconstruction. Overall, it appears that these types of radical surgery are less frequently performed; however, when required, multidisciplinary teams at high-volume centers can potentially improve short-term morbidity. There are few data to examine the long-term, quality-of-life outcomes after reconstruction following oncologic resection in advanced and recurrent gynecologic cancers. In this review we outline considerations and approaches for reconstruction after surgery for gynecologic cancers. We also discuss areas of innovation, including minimally invasive surgery and the use of 3D surgical anatomy models for improved surgical planning.In the era of 'less is more', pelvic exenteration in gynecologic oncology is still indicated when there are no other curative-intent alternatives in persistent or recurrent gynecological malignancies confined to the pelvis or with otherwise unmanageable symptoms from fistula or radiation necrosis. Pelvic exenteration is one of the most destructive procedures performed on an elective basis, which inevitably carries a significant psychologic, sexual, physical, and emotional burden for the patient and caregivers. Such complex ultraradical surgery, which requires removal of the vagina, vulva, urinary tract, and/or gastrointestinal tract, subsequently needs creative and complex reconstructive procedures. The additional removal of sidewall or perineal structures, like pelvic floor muscles/vulva, or portions of the musculoskeletal pelvis, and the inclusion of intra-operative radiation further complicates reconstruction. This review paper will focus on the reconstruction aspects following pelvic exenteration, including options for urinary tract restoration, reconstruction of the vulva and vagina, as well as how to fill large empty spaces in the pelvis. While the predominant gastrointestinal outcome after exenteration in gynecologic oncology is an end colostomy, we also present some novel new options for gastrointestinal tract reconstruction at the end.
All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25-mm slice thickness using a thermoplastic mask for immobilization. To achieve conformal hippocampal sparing during the delivery of WBRT, the technique of volumetric modulated arc therapy (VMAT) via Linac-based RapidArc® or TrueBeamTM is employed in our treatment planning. All treatment plans are delivered by using the Linac Varian-iX or TrueBeamTM. In terms of dose prescription, a dose of 30 Gy in 15 fractions is prescribed to whole-brain planning target volume (PTV) under the setting of prophylactic cranial irradiation for NSCLC patients.
All subjects are asked to come to the movement laboratory of Maastricht University Medical Centre on one individual day. Before gait analyses the following characteristics were measured; height, weight, BMI, knee and ankle width (measured between the two condyles of the knee and the measured between the two malleoli of the ankle) and leg length . All measurements are performed by researchers who was trained in the examination of the foot. At least one static trial was performed with all 42 markers, with the subjects in stance phase in an anatomic neutral position. After calibrating the markers and calculating the subject-specific joint axes in the static trial, 6 markers were removed, according to the OFM protocol. After that the subjects were asked to walk barefoot in normal speed after a number of practice trials. For this speed at least 8 proper recordings were made during walking. The healthy subjects were also asked to walk in slow speed and 8 proper recordings were made during this slow-speed walking. One whole step was considered complete from heel landing (initial contact) to toe-off. A force plate was used to determine the heel-strike and toe-off phase during walking. Corrections in the axes of the knee and ankle were made if necessary and tiles were saved for further data output.